Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03338816
Other study ID # ALN-AS1-003
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 16, 2017
Est. completion date May 31, 2021

Study information

Verified date May 2022
Source Alnylam Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).


Recruitment information / eligibility

Status Completed
Enrollment 94
Est. completion date May 31, 2021
Est. primary completion date January 31, 2019
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - = 12 years of age - Diagnosed with Acute Hepatic Porphyria (Acute Intermittent Porphyria, Hereditary Corproporhyria, Variegate Porphyria, aminolevulinic acid (ALA) dehydratase deficient porphyria) - Elevated urinary or plasma porphobilinogen (PBG) or ALA values within the past year, - Have active disease, with at least 2 documented porphyria attacks within the last 6 months - Willing to discontinue or not initiate the use of prophylactic hemin throughout the study. - Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception Exclusion Criteria: - Clinically significant abnormal laboratory results - Anticipated liver transplantation - History of multiple drug allergies or intolerance to subcutaneous injections - Active HIV, hepatitis C virus, or hepatitis B virus infection(s) - History of recurrent pancreatitis

Study Design


Intervention

Drug:
Givosiran
Givosiran by SC
Placebo
Matching placebo (normal saline [0.9% NaCl]) by SC

Locations

Country Name City State
Australia Clinical Trial Site Auchenflower
Australia Clinical Trial Site Camperdown
Australia Clinical Trial Site Parkville Victoria
Bulgaria Clinical Trial Site Sofia
Canada Clinical Trial Site Edmonton
Denmark Clinical Trial Site Odense
Finland Clinical Trial Site Helsinki
France Clinical Trial Site Paris
Germany Clinical Trial Site Chemnitz
Germany Clinical Trial Site Munich
Italy Clinical Trial Site Modena
Japan Clinical Trial Site Hamamatsu
Japan Clinical Trial Site Iizuka
Japan Clinical Trial Site Tokyo
Korea, Republic of Clinical Trial Site Seoul
Mexico Clinical Trial Site Mexico City
Netherlands Clinical Trial Site Rotterdam
Poland Clinical Trial Site Warsaw
Spain Clinical Trial Site Barcelona
Spain Clinical Trial Site El Palmar
Spain Clinical Trial Site Pamplona
Sweden Clinical Trial Site Stockholm
Taiwan Clinical Trial Site Taichung
Taiwan Clinical Trial Site Taipei city
Taiwan Clinical Trial Site Taoyuan city
United Kingdom Clinical Trial Site London
United States Clinical Trial Site Ann Arbor Michigan
United States Clinical Trial Site Boston Massachusetts
United States Clinical Trial Site Galveston Texas
United States Clinical Trial Site Little Rock Arkansas
United States Clinical Trial Site New York New York
United States Clinical Trial Site Philadelphia Pennsylvania
United States Clinical Trial Site Salt Lake City Utah
United States Clinical Trial Site San Francisco California
United States Clinical Trial Site Seattle Washington
United States Clinical Trial Site Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Alnylam Pharmaceuticals

Countries where clinical trial is conducted

United States,  Australia,  Bulgaria,  Canada,  Denmark,  Finland,  France,  Germany,  Italy,  Japan,  Korea, Republic of,  Mexico,  Netherlands,  Poland,  Spain,  Sweden,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP) Porphyria attacks were defined as meeting all of the following criteria: an acute episode of neurovisceral pain in the abdomen, back, chest, extremities and/or limbs, no other medically determined cause, and required treatment with intravenous (IV) dextrose or hemin, carbohydrates, or analgesics, or other medications such as antiemetics at a dose or frequency beyond the participant's usual daily porphyria management. The annualized rate of porphyria attacks is a composite endpoint which included porphyria attacks requiring hospitalization, urgent healthcare visit, or IV hemin administration at home. 6 months
Secondary The Pharmacodynamic (PD) Effect of Givosiran on Urine Levels of Delta-aminolevulinic Acid (ALA) in Participants With AIP The PD effect of givosiran was evaluated by spot urine ALA levels normalized to spot urine creatinine levels. 3 and 6 months
Secondary The PD Effect of Givosiran on Urine Levels of Porphobilinogen (PBG) in Participants With AIP The PD effect of givosiran was evaluated by spot urine PBG levels normalized to spot urine creatinine levels. 6 months
Secondary Annualized Rate of Hemin Administration in Participants With AIP Annualized rate of hemin doses was evaluated as annualized days of hemin use. 6 months
Secondary Annualized Rate of Porphyria Attacks in Participants With AHP Porphyria attacks were defined as meeting all of the following criteria: an acute episode of neurovisceral pain in the abdomen, back, chest, extremities and/or limbs, no other medically determined cause, and required treatment with intravenous (IV) dextrose or hemin, carbohydrates, or analgesics, or other medications such as antiemetics at a dose or frequency beyond the participant's usual daily porphyria management. The annualized rate of porphyria attacks is a composite endpoint which included porphyria attacks requiring hospitalization, urgent healthcare visit, or IV hemin administration at home. 6 months
Secondary Area Under the Curve (AUC) of the Change From Baseline in Weekly Mean Score of Daily Worst Pain as Measured by the Brief Pain Inventory-Short Form (BPI-SF) Numeric Rating Scale (NRS) in Participants With AIP Participants rated worst daily pain score in an eDiary using the 11-point BPI-SF NRS, in which 0=no pain and 10=worst pain. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the post baseline weekly mean score minus the baseline score. Lower scores indicate an improvement. The 6-month AUC was calculated based on change from baseline in weekly mean scores. Baseline and 6 months
Secondary Average Change From Baseline in Weekly Mean Score of Daily Worst Pain as Measured by the Brief Pain Inventory-Short Form (BPI-SF) Numeric Rating Scale (NRS) in Participants With AIP Participants rated worst daily pain score in an eDiary using the 11-point BPI-SF NRS, in which 0=no pain and 10=worst pain. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement. Baseline and 6 months
Secondary AUC of the Change From Baseline in Weekly Mean Score of Daily Worst Fatigue Score as Measured by the Brief Fatigue Inventory-Short Form (BFI-SF) NRS in Participants With AIP Participants rated daily worst fatigue score in an eDiary using the 11-point BFI-SF NRS, in which 0=no fatigue and 10=worst fatigue. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the post baseline weekly mean score minus the baseline score. Lower scores indicate an improvement. The 6-month AUC was calculated based on change from baseline in weekly mean scores. Baseline and 6 months
Secondary Average Change From Baseline in Weekly Mean Score of Daily Worst Fatigue Score as Measured by the Brief Fatigue Inventory-Short Form (BFI-SF) NRS in Participants With AIP Participants rated daily worst fatigue score in an eDiary using the 11-point BFI-SF NRS, in which 0=no fatigue and 10=worst fatigue. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement. Baseline and 6 months
Secondary AUC of the Change From Baseline in Weekly Mean Score Daily Worst Nausea Score as Measured by NRS in Participants With AIP Participants rated worst daily nausea score in an eDiary using an 11-point NRS, in which 0=no nausea and 10=worst nausea. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement. The 6-month AUC was calculated based on change from baseline in weekly mean scores. Baseline and 6 months
Secondary Average Change From Baseline in Weekly Mean Score Daily Worst Nausea Score as Measured by NRS in Participants With AIP Participants rated worst daily nausea score in an eDiary using an 11-point NRS, in which 0=no nausea and 10=worst nausea. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement. Baseline and 6 months
Secondary Change From Baseline in the Physical Component Summary (PCS) of the 12-Item Short Form Survey (SF-12) in Participants With AIP The SF-12 is a survey designed for use in patients with multiple chronic conditions. This 12-item scale can be used to assess the physical and mental health of respondents. 10 of the 12 questions are answered on a 5 point likert scale and 2 are answered on a 3 point likert scale. The questions are then scored and weighted into 2 subscales, physical health and mental health. Respondents can have a score that ranges from 0-100 with 100 being the best score and indicating high physical or mental health. A 3 point change in SF-12 score reflects a meaningful difference. A higher score indicates improvement. Baseline and 6 months
See also
  Status Clinical Trial Phase
Terminated NCT02922413 - Panhematin for Prevention of Acute Attacks of Porphyria Phase 2
Completed NCT02949830 - A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) Phase 1/Phase 2
Completed NCT02943213 - Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride Phase 1
Completed NCT02082860 - Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria Phase 1
Completed NCT02452372 - A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) Phase 1
Completed NCT00418795 - Porphozym in the Treatment of Acute Attacks in AIP Phase 2/Phase 3
Active, not recruiting NCT01617642 - Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
Completed NCT02076763 - Observational Study of Acute Intermittent Porphyria Patients N/A
Active, not recruiting NCT02935400 - Acute Porphyria Biomarkers for Disease Activity